Limit Patient Cost-Sharing: States Tell Payers
Insurers are trapped between pharmaceutical companies developing increasingly expensive drug treatments, and states that want to reduce the patient-burden of co-pays. Additionally, states like New York and Alaska have banned payers from using specialty formularies.
"Value" Decision by NICE Met With Disapproval
Both, the scientific community and a charitable organization, Prostate Cancer UK, have criticized the drug approval body for not offering abiraterone to sufferers until after chemotherapy.